Astex President Awarded Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery

Astex Pharmaceuticals, Inc. (ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that its president and director, Harren Jhoti, PhD, will be presented with the 2012 Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry. The biennial award recognizes research and innovation with respect to technology in drug discovery.

"I am honored to be bestowed this award by the Executive Committee of the European Federation for Medicinal Chemistry," said Dr. Jhoti. "This award recognizes the leading position that the Astex team has established in fragment-based drug discovery, a technique now widely used by the pharmaceutical sector to discover high quality drug candidates. It is my hope that our contributions to fragment-based drug discovery will help to produce effective medicines."

SciClone Reports Financial Results for the Second Quarter 2012

Continued Strong Revenue Growth for ZADAXIN(R), as Well as Primary Care and Oncology Product Lines

SciClone Pharmaceuticals, Inc. (SCLN) today reported financial results for the second quarter and for the six months ended June 30, 2012. Results showed strong continued revenue growth on a quarterly and year-to-date basis for ZADAXIN®, the Company's flagship product, as well as for the primary care and oncology businesses in China.

Amarin Reports Second Quarter 2012 Financial Results and Provides Update on Operations

Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended June 30, 2012 and provided an update on company operations.

Amarin noted the following highlights of progress made since the quarter ended March 31, 2012:

• FDA approval of Vascepa^TM (icosapent ethyl) capsules as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG>=500 mg/dL) hypertriglyceridemia

  Published: 09 August 2012

  Written by Editor

  Nasdaq   Healthcare   Financial Results   Up on News   Interesting News  

  Read more: Amarin Corporation plc ( AMRN )

Halozyme Reports Second Quarter 2012 Financial Results

Halozyme Therapeutics, Inc. (HALO) today reported financial results for the quarter ended June 30, 2012.

"With receipt of the complete response letter for the HyQ BLA, we will be working to address the questions raised by FDA's Blood Products Division regarding the subcutaneous plasma derivatives programs," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "We are also pleased that after a review of the most recent safety data submitted, we have confirmation from FDA's Drug Division that no action is required on our approved product, Hylenex, or clinical programs under the Hylenex IND."